title: Pamidronate attenuates muscle loss after pediatric burn injury.
abstract: Children who are burned >40% total body surface area lose significant quantities of both bone and muscle mass because of acute bone resorption, inflammation, and endogenous glucocorticoid production, which result in negative nitrogen balance. Because administration of the bisphosphonate pamidronate within 10 days of the burn injury completely prevents the bone loss, we asked whether muscle protein balance was altered by the preservation of bone. We reviewed the results from 17 burned pediatric subjects previously enrolled in a double-blind randomized controlled study of pamidronate in the prevention of post-burn bone loss and who were concurrently evaluated for muscle protein synthesis and breakdown by stable isotope infusion studies during the acute hospitalization. We found a significantly lower fractional protein synthesis rate (FSR) in the pamidronate group and a correspondingly lower rate of appearance of the amino acid tracer in venous blood, suggesting lower muscle protein turnover. Moreover, net protein balance (synthesis minus breakdown) was positive in the subjects receiving pamidronate and negative in those receiving placebo. Muscle fiber diameter was significantly greater in the pamidronate subjects and leg strength at 9 months post-burn was not different between subjects who received pamidronate and normal physically fit age-matched children studied in our lab. Leg strength in burned subjects who served as controls tended to be weaker, although not significantly so. If substantiated by a larger study, these results suggest that bone may have a paracrine mechanism to preserve muscle and this finding may have implications for the treatment of sarcopenia in the elderly.
authors.affiliation: Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA; Shriners Hospital for Children, Galveston, TX, USA.
authors.forename: Elisabet
authors.initials: E
authors.lastname: Børsheim
authors.forename: David N
authors.initials: DN
authors.lastname: Herndon
authors.forename: Hal K
authors.initials: HK
authors.lastname: Hawkins
authors.forename: Oscar E
authors.initials: OE
authors.lastname: Suman
authors.forename: Matthew
authors.initials: M
authors.lastname: Cotter
authors.forename: Gordon L
authors.initials: GL
authors.lastname: Klein
mesh_terms: D000293:Adolescent; D001706:Biopsy; D002056:Burns / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009124:Muscle Proteins / Q000378:metabolism; D009132:Muscles / Q000187:drug effects / Q000473:pathology*; D000077268:Pamidronate; D010649:Phenylalanine / Q000097:blood; D010919:Placebos; D014176:Protein Biosynthesis
chemical_list: D004164:Diphosphonates; D009124:Muscle Proteins; D010919:Placebos; D010649:Phenylalanine; D000077268:Pamidronate
keywords: BONE AND MUSCLE LOSS; BURN INJURY; PAMIDRONATE